Vanda Pharmaceuticals Boosts Revenue Guidance on Strong Fanapt Sales and NEREUS Launch

Event summary

  • Fanapt® net product sales rose 26% to $29.6 million in Q1 2026, with total prescriptions up 32% and new-to-brand prescriptions surging 76%.
  • NEREUS™ (tradipitant) launched via nereus.us, a direct-to-consumer platform for motion-induced vomiting prevention.
  • Full-year 2026 revenue guidance raised to $240-$290 million, including $10-30 million from newly launched NEREUS™.
  • BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia on February 20, 2026.
  • FDA accepted the Biologics License Application (BLA) for imsidolimab in Generalized Pustular Psoriasis with a PDUFA target action date of December 12, 2026.

The big picture

Vanda Pharmaceuticals is positioning itself for continued growth through strategic product launches and regulatory milestones. The company's focus on innovative therapies and direct-to-consumer platforms reflects broader industry trends towards patient-centric models and digital health solutions. With a raised revenue guidance and a robust pipeline, Vanda aims to address high unmet medical needs and improve patient outcomes.

What we're watching

Commercial Momentum
Whether Vanda can sustain the strong momentum of Fanapt® and successfully scale the direct-to-consumer model for NEREUS™.
Regulatory Milestones
The pace at which Vanda advances its pipeline, particularly the FDA review of imsidolimab for Generalized Pustular Psoriasis.
Financial Discipline
How Vanda balances continued investment in new product launches and pipeline advancement with its cash position.